The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, represents a complex several-stage organic process. Preliminary routes focused on protein section coupling, utilizing solid-phase synthesis methodologies to build the long protein sequence. Subsequent investigation has explored different approaches, including